SEC Form 4 · accession 0001209191-18-041091
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Jun 29, 2018
Accepted (ET)
Jul 3, 2018 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2018 | M | 1,796 | $91.05 | A | 71,795 | D | |
| Common Stock | Jun 29, 2018 | M | 11,649 | $86.52 | A | 83,444 | D | |
| Common Stock | Jun 29, 2018 | S | 7,535 | $161.57 | D | 75,909 | D | |
| Common StockF2,F3 | Jun 29, 2018 | S | 31,796 | $165.46 | D | 44,113 | D | |
| Common Stock | Jun 29, 2018 | S | 5,000 | $167.04 | D | 39,113 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $91.05 | Jun 29, 2018 | M | 1,796 | D | — | Feb 1, 2026 | Common Stock | 1,796 | 12,572 | D |
| Stock Option (Right to Buy)F5 | $86.52 | Jun 29, 2018 | M | 11,649 | D | — | Feb 2, 2027 | Common Stock | 11,649 | 25,629 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $165.46 (range $165.13 to $166.05).
- F3Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4The option vests in 16 quarterly installments from 2/2/2016.
- F5The option vests in 16 quarterly installments from 2/3/2017.